(Inflammatory Markers of Coronary Risk)
CRP(hs-CRP), fibrinogen, serum amyloid A(SAA)
adhesion molecule 1 (ICAM- 1), vascular-cell adhesion molecule 1 (VCAM-1), E-selectin,
soluble intercellular adhesion molecule 1 (ICAM-1), vascular-cell adhesion molecule 1
REFERENCE S
1. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis:
An assessment of the evidence and need for future research . Circulation 1997;96:4095-4 103.
2. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease:is there a link ? Lancet 1997;350:430-436.
3. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115- 126.
4. Ridker DJ. Inflammatory markers of coronary risk . N Engl J Med 2000; 343:1179-1182.
5. Melnick JL, Adam E, DeBakey ME. Possible role of Cytomegalovirus in atherogenesis. JAMA 1990;263:2204.
6. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated
with cardiac allograft rej ection and atherosclerosis. JAMA 1989;26 1:356 1.
7. McDonald K, Rector TS, Blaulan EA, et al. Association of coronary artery disease incardiac transplant recepients with cytomegalovirus infection . Am J Pathol 1989;64:359.
8. Lemstrom K, Sihvola R, Bruggeman C, et al. Cytomegalovirus infection-enhanced cardiac
vasculopathy is abolished by DHPG prophylaxis in the rat . Circulation 1997;95:26 14.
9. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novelchlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction . Lancet 1988;2:983-985.
10. Cook PJ, Honeybourne D, Lip GY, et al. Chlamydia pneumoniae antibody titers are
Birmingham Stroke Proj ect . Stroke 1998;29:404-4 10.
atherosclerosis of the carotid artery . Circulation 1995;92:3397-3400.
12. Campbell LA, O'Brien ER, Cappuccio AL: Detection of Chlamydia pneumoniae TWAR in
human coronary atherectomy tissues. J Infect Dis 1995;172:585.
13. Markus HS, Sitzer M, Carrington D, et al. Chlamydia pneumoniae infection and early
asymptomatic carotid atherosclerosis. Circulation 1999;100:832-837.
14. Weiss SM, Robin PM, Gaydos CA, et al. Failure to detect Chlamydia pneumoniaein
coronary atheromas of patients undergoing atherectomy . J Infect Dis 1996;173:957.
15. Ramitrez JA : Isolation of Chlamydia pneumoniae from the coronary artery of a patient
with coronary atherosclerosis. Ann Intern Med 1996;125:979.
16. Patel P, Mendall MA, Carrington D, et al. Association of Helicobacter pylori and
Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. Br Med J 1995;11:7 11.
17. Mendall MA, Patel P, Ballam L, et al. C-reactive protein and its relationship to
cardiovasciular risk factors: a populational based cross sectional study . Br Med J 1996;3 12:106 1.
18. Xu Q, Wick G: The role of heat shock proteins in protection and pathophysiology of the
arterial wall. Mol Med Today 1996;2:372.
19. Fong IW, Chiu B, Viira E, Mahony J: Rabbit model of Chlamydia pneumoniae infection .
20. Moazed TC, Kuo CC, Grayston JT, et al. Murine models of Chlamydia pneumoniaeinfection and atherosclerosis. J Infect Dis 1997;175:883.
2 1. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with C. pneumoniaeaccelerates the development of atherosclerosis and treatment with azithromycin prevents it in arabbit model. Circulation 1998;97:633-636.
22. Gupta S, Leatham EW , Carrington D, et al. Elevated Chlamydia pneumoniae antibodies,cardiovascular events, and azithromycin in male survivors of myocardial infarction . Circulation 1997;96:404-407.
23. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial ofazithromycin in patients with coronary artery disease and serological evidence for Chlamydiapneumoniae
Myocardial Infection with Chlamydia (ACADEMIC) study . Circulation 1999;99:1540-1547.
24. Muhlenstein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trialof azithromycin in patients with coronary artery disease: primary clinical results of theACADEMIC study . Circulation 2000;102:1755-1760.
25. Mendall MA, Goggin PM, Molineaux N , et al. Relation of Heliocobacter pylori infectionand coronary heart disease. Br Heart J 1994;7 1:1437.
26. Whincup PH, Mendall MA, Perry IJ, et al. Prospective relations between Helicobacterpylori infection, coronary artery disease and stroke in middle aged men . Heart 1996;75:568.
27. Martin-de-Argila C, Boixeda D, Canon R, et al. A high seroprevalence of Helicobacterpylori infection in coronary heart disease. Lancet 1995;346:3 10.
28. Wald NJ, Law MR, Morris JK, et al. Helicobacter pylori infection and mortality fromischemic heart disease: negative result from a large, prospective study . Br Med J 1997; 3 15:1199.
29. Parente F, Porro GB. The association between Helicobacter pylori infection and ischemicheart disease: facts or fancy ? Helicobacter 1997;2(suppl 1):S67.
30. Blasi F, Denti F, Erba M. Detection of Chlamydia pneumoniae but not Helicobacter
pylori in atherosclerotic plaques of aortic aneurysm . J Clin Microbiol 1996;34:2766.
3 1. Humphries SE, Luong LA, Montgomery HE, et al. Gene-environment interaction in thedetermination of levels of plasma fibrinogen . Thromb Haemost 1999;82:818-825.
32. Ridker PM. High-sensitivity C-reactive protein . Potential adj unct for global assessment in
the primary prevention of cardiovascular dusease. Circulation 2000;103:181-1818.
33. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk ofcardiovascular disease in apparently healthy men . N Engl J Med 1997;336:973-979.
34. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers ofinflammation in the prediction of cardiovasculr disease in women .
phospholipase A(2) predict coronary events in patients with coronary artery disease.
36. Packard CJ, O'Reilly DSJ, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 asan independent predictor of coronary heart disease. N Engl J Med 2000;343:1148-1155.
concentration of soluble intercellular adhesion molecule 1 and risks of future myocardialinfarction in apparently healthy men . Lancet 1998;35 1:88-92.
38. Ridker PM, Rifai N , Stampfer MJ, Hennekens CH . Plasma concentration of interleukin-6and the risk of future myocardial infarction among apparently healthy men . Circulation 2000;10 1:1767- 1772.
39. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V . Inflammation, obesity, stress andcoronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148:209-2 14.
40. Lindahl B, Toss H, Siegbahn A, et al, for the FRISC Study Group . Markers ofmyocardial damage and inflammation in relation to long-term mortality in unstable coronaryartery disease. N Engl J Med 2000;343:1139-1147
4 1. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleuken (IL)-1Ra andIL-6 during the first 2 days of hospitalization in unstable angina are associated with increasedrisk of in-hospital coronary events. Circulation 1999;99:2079-2084
42. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive proteinand serum amyloid A protein in severe unstable angina. N Engl J Med 1994;33 1:4 17-424.
43. Buffon A, Liuzzo G, Biasucci L, et al. Preprocedural serum levels of C-reactive proteinpredict early complications and late restenosis after coronary angioplasty . J Am Coll Cardiol. 1999;34:15 12- 152 1.
44. Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein aftersuccessful coronary-artery stenting in patients with stable angina. Am J Cardiol 1998;82:5 15-5 18.
45. Versaci F, Gaspardone A, Tomai F, et al. Predictive value of C-reactive protein inpatients with unstable angina pectoris undergoing coronary stent implantation . Am J Cardiol 2000;85:92-95.
46. Gottsauner-Wolf M, Zasmeta G, Hornykewycz M, et al. Plasma levels of C-reactiveprotein after coronary stent implantation . Eur Heart J 2000;2 1:1152-1158.
47. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppress the rise in levels ofcirculating inflammatory markers after percutaneous coronary revascularization . Circulation 200 1;104:163- 167.
48. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk ofcoronary events after acute myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-844.
49. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductaseinhibitor therapy on high sensitive C-reactive protein levels. Circulation 200 1;103:1933-1935
Information for Health Care Professionals Marihuana (marijuana, cannabis ) dried plant for administration by ingestion or other means This document has been prepared for the Drug Strategy and Controlled Substances Programme to provide information on the use of marihuana for medical purposes. Marihuana is not an approved therapeutic product and the provision of this information should n